Introduction
Pharmacological toxicity studies are designed to examine the relationship between the dose of a therapeutic agent and the potential toxic effect of that agent on some population. When the total number of subjects is fixed and a set of possible dose levels is given, an experimental design is completely determined by the rule that allocates dose levels to subjects. Such designs are among those called dose-response designs. A principal goal of many such studies is to estimate a quantile, the dose level at which a desired probability of response is attained.
Consider a dose-response design in which subjects are sequentially assigned to one of K dose levels of a drug and subject response is dichotomous (toxic/nontoxic).
Durham and Flournoy (1994) describe a family of designs where subjects are sequentially assigned to the next higher, same, or next lower dose level, with some probability that is dependent upon the previous subject's response. Their designs are a randomized extension of Dixon and Mood's (1948) up-and-down design. They belong to the class of random walk rules because the allocation scheme induces a random walk on the lattice of dose levels. Particular random walk rules have been studied by Derman (1957) and Tsutakawa (1967 Tsutakawa ( , 1972 , for example.
Strategies for sequential dose-response designs include up-and-down methods, stochastic approximation methods, maximum likelihood methods, and Bayesian methods. A brief history is as 2. A Random Walk Rule Let xI, .. ., XK be an ordered set of doses. As in most dose-response methodology, we assume that both efficacy and toxicity are monotonically related to dose. Hence, our goal is to find the highest tolerable (defined by investigators) dose. Durham and Flournoy (1994) describe a broad class of random walk rules, of which the Biased Coin Design II (BCD) (Durham and Flournoy, 1995, p. 145 ) is a special case and is as follows.
If patient j has just been assigned to dose level xi, assign patient j + 1 with the following rule: If patient j experienced a toxic response, then assign patient j + 1 to level xi-I. If patient j had no toxic response, then flip a biased coin with probability of heads b E [0,0.5]. If it lands heads up, assign patient j + 1 to level xi+I. If it lands heads down, assign patient j + 1 to xi.
It is necessary to impose boundary conditions, as one cannot lower the dose level at xI or raise the dose level at XK. For our purposes, we simply assign the patient to xI or XK, respectively, if such conditions occur. This is a fairly conservative scheme in that one always lowers the dose level if there is a toxicity. For a nontoxicity, b is the probability of increasing the dose level. Shortly it will be shown how to set b in order to target a specific quantile of the dose-response curve.
Let pi be the probability of toxicity at dose level xi. Let p {P1,... ,PK }. The distribution of NV(n)/n, the proportion of subjects treated at dose level xi, will be of great interest to us for ethical reasons, as we want to develop a rule that will place as few patients as possible at risk of being assigned to highly toxic dose levels. Asymptotic properties of Ni(n)/n are given in . In particular, the asymptotic treatment allocation proportions are given by {r = 7rl,... ., w 7K} in a closed-form function of p. Of greater interest are finite distributional results , including the mean, variance, and covariances of Ni(n)/n for any n. These are useful in determining the probability of assigning patients to dose levels in the subspace {X = ,xw, *X** , XK }, where xu is some dose level that is considered undesirable.
Another primary ethical parameter of interest is R(n)/n, the total proportion of toxic responses. Rosenberger and Sriram (1997) establish the almost sure convergence of R(n)/n to p ir, while Flournoy et al. (1995) give the mean and variance of R(n) for any n, together with a central limit theorem.
Thus, exact finite and asymptotic distributional properties are known that are useful in checking the ethical consequences of a particular design. We compute these via a program in MATLAB for any p and any number of design points.
Let p, be an unknown quantile of the dose-response curve corresponding to IF (0, 1); that is, p, is the maximum dose level deemed tolerable. A goal of the BCD is to center the frequency distribution of design points (i.e., treatments) around a specific, but unknown, quantile. For BCD, choosing b such that b = F/(I -F), F < 0.5, will asymptotically center the allocation proportions unimodally around ,u, whenever pt is properly contained in the dose space (cf., Durham and Flournoy, 1994) . For instance, if one wants to target the 33rd percentile of the dose-response curve, then by selecting b= 1/2, the asymptotic distribution of dose level assignments will be centered around Pt. When comparing starting rule (1) for the BCD with the same starting rule for the CRM, the similarities are compelling. Expected total toxicity differed by, at most, 3%, with the BCD doing slightly better under scenarios A and B. Expected allocation proportions were also very close. For the BCD with starting rule (2), the expected proportion of toxicities was less for scenario C, but slightly worse than starting rule (1) for scenarios A and B. Under scenario C, we have a case where the target quantile is out of range of the space of doses. Clearly, we cannot sample around the target quantile in this case using either the BCD or CRM. However, the mode is at the extreme end of the dose range closest to p,. For the other two cases, the unimodality property around Pt for the BCD seems to hold well for these small sample studies. 
Small Sample
for some distribution function F and constants a and 3. For the location-scale family in (1), it is easy to see that the maximum likelihood estimator of ,u is given by 1 Flr +c 2 
one can use a standard logistic regression package to find & and 3 and compute a via (2) for any value of F. In the Appendix, we derive the usual approximation to the asymptotic variance from the Fisher's information matrix, which suggests the following natural estimator of the variance of A:
where i = 1-Pi and Pi is the observed proportion of toxicities at dose level xi. Of course, expressions analogous to (4) can also be derived under a probit, Weibull, exponential, or other appropriate model.
Nonparametric Estimators
As random walk rules place design points unimodally around the target quantile, this suggests that the empirical mode of the assignment distribution would be one possible estimator of the target quantile. Derman (1957) proves that his biased coin random walk rule, asymptotically, causes the empirical mode to be within A\ of pu for arbitrary F. This is also true for BCD (cf., Durham and Flournoy, 1994 ) and for other biased coin designs constructed using random walk theory (cf., . In the continual reassessment method, one goal of the design is to place design points sequentially closer to the target quantile, leaving the value of the last design point as the estimate of the target quantile. This is similar in spirit to using the mode as an estimator for the random walk rules. The disadvantage of these estimators for the continual reassessment method and the random walk rules is that they can only be taken from a discrete set of values. Other estimators, such as the maximum likelihood estimator, can take on values between assigned dose levels, which is attractive in the event that the target quantile falls below the lowest dose level or above the highest dose level. Many have studied the use of the empirical mean 
A Comparison of Estimators
A simulation study of the performance of the maximum likelihood estimator, the empirical mean, and the mode is given in Table 2 for sample sizes of 25 and 50. The start-up rule described in Section 3 was used with BCD. For small samples, the maximum likelihood estimator is relatively unbiased, but has a fairly large variability. A big disadvantage to maximum likelihood estimation in the logistic model is the existence problems that arise when Silvapulle's (1981) conditions are violated. Nonconvergence is likely to occur from time to time with small samples. At a sample size of 50, the maximum likelihood estimator is much more efficient. The mode tends to be biased and has fairly large variability for small and medium-sized samples. The empirical mean has the smallest variability of all the estimators at all the quantiles studied here.
Redesigning an Experiment in Bone Marrow Transplantation:
An Example Flournoy (1993) described an experiment in which the target proportion of observed toxicities was r = 0.10. Possible dosages of cyclophosphamide (mg/kg/day), xo = {31,49,67,85,103, 121}, were identified according to the Bayesian method of Tsutakawa (1980) , which minimizes the posterior variance around the target dose ft. An up-and-down strategy was conducted on x0o. First, using the same design points as were used by Flournoy (1993), we show the effect that using the BCD would have had on her experiment. Then we describe an alternative method for selecting design points. Empirical results after the experiment was concluded indicate that the dose-response function increased sharply, much more sharply than even the conservative prior (see Figure 1 ). Silvapulle's (1981) conditions were violated, and hence maximum likelihood estimates of the logistic response function did not exist. Here, the data set is augmented by one additional trial, that was assumed to produce a failure, in order to allow maximum likelihood estimation. We call the estimates based on the augmented data set (n = 34) empirical estimates of the logistic response function and use these for illustrative purposes. The empirical estimates are Oemp =-4.7
and Temp = 0.0974. The empirical shape parameter is 50% larger than the conservative prior, TO The consequences of the conservative prior response function's being so far below the empirical response function were severe. Flournoy's (1993) design called for an ad hoc modified up-and-down rule to be used on the design points in xo. The rule was to treat in groups of four; increase the dose if no toxicity was seen; use the same dose if there were one out of four toxicities; and decrease the dose if there were two or more toxicities. This was fortunate because it caused only lower dose levels in xo to be used. However, the data indicate that the range of dosages in the design failed to cover the target dose; the empirical target dose is fLemp -25.7 mg/kg, which is below the lowest dose (31 mg/kg) in the design. Certainly, having more information about the response function at lower dosages would have been useful. In this section, we show that using BCD would have provided more useful information with the same number of patients, even when starting far from the target. Figure 2 shows the treatment distribution after 34 trials that can be expected using BCD under the median prior, the conservative prior, and the empirical response functions. Everything except the treatment allocation rule is the same as was used by Flournoy (1993); namely, the design lattice is xo and the initial dose is X3= 67, which is the nearest possible dose below Ao.o50. 
Allocation Proportions Across the Design Lattice

The Empirical Mean as an Estimator of ,u
When treatments concentrate symmetrically around thestarget, any measure of central tendency may be used to estimate ,u. In particular, when symmetric treatment distributions are obtained (approximately), the mean of the treatment distribution, given in (5), is a plausible estimate of the target dose. asymptotic average dose with the bias correction (see Section 5.5) is within rounding error of the target dose. For both the conservative prior and empirical response functions, the lack of design points below the target causes the treatment distribution to skew, as shown in Figure 2 , and this skewness causes E{X(n)} to overestimate the target dose, even in the limit. However, when a sufficiently fine mesh is used, as when a step size of 6 is used with the empirical response function, the average dose performs well. The bias correction is seen to improve the performance of this estimator when the allocation distribution is roughly symmetric. 
An Adjusted Empirical Mean Estimator of p, For large samples or when the starting treatment is close to ,t, it is not surprising that the treatment mean underestimates
which is very close to the asymptotic mean of the treatment distribution, xo -r = 67.5. The form of (7) indicates that, so long as zA is positive and IF = 0.50, (5) will be a biased estimator of p and that (ignoring for the moment bias induced by selecting an initial treatment far from p) a better estimator is Table 3 Using the expected average dose to estimate the quantile corresponding to 10% toxicity
Response function
Median prior Conservative prior Empirical
Step 
Note that the bias correction is always less than the step size A. The expectation of this estimator is shown in Figure 4 with bounds at ?1 standard deviation. Note from Table 3 that, when the treatment distribution is symmetric asymptotically, the correction is consistent for IL. Thus when the treatment distribution is evolving symmetrically, but an estimate of 1a is desired before E{X(n)} levels off, the asymptote of (8) Table 4 .
Of course at n = 1, the expected proportion of toxicities is the probability of toxicity. We focus initially on these points in Figure 5 Table 4 Expected proportion of toxicities targeting F = 0.10
Response function Median prior Conservative prior Empirical
Step ... Although the method of reducing the step size after every trial has distinct theoretical advantages, its practical implementation may require fairly complicated 'equipment. A simple approximation is to reduce the step size by a proportionate amount after one or more complete runs (a run is defined to be a series of steps in one direction only). A convenient practical procedure is to halve the step size after the first, third, seventh, ..., 2"th run.
Empirical sampling trials (Wetherill, 1963) indicate that, if the spread and location of the response function are known within reasonable limits ..., then a very good approximation to the Robbins and Monro efficiency is obtained by halving the step size only once, preferably after the 3rd run.
We now motivate the design lattice xi.
Design to Control Toxic Events
Another goal is to avoid highly toxic dose levels. Suppose we want 97.5% of the treatments to be less than or equal to some unknown dose pli for which P{Y= 1 It1} 1= 1, F1 > F = 0.10. From (6), it can be seen that the stationary allocation distribution for the BCD is a mixture of two discrete normal distributions with common scale parameter z\/T; thus, the spread around A, can be controlled by setting 2(z\/r)1/2 equal to ,l -A and solving for A\ to yield A prior estimate T can be used to determine A\. One could consider updating /\ at each trial by sequentially estimating T or updating in stages when the empirical and prior estimates differ substantially.
Consider A\ to be fixed for the duration of the experiment. The step size found by replacing T in equation (9) If we wish to protect against treating at levels for which P{toxicity} > 0.40, we set \ = 6 and take the lattice of design points to be AL0.50 + 3, ,A0.50 i 9.... For Flournoy's design, such  a lattice would be x1= {5.4,..., 71.4, 77.4,. . .}. Using this lattice of points with the BCD, the empirical response function would allocate treatments as shown in Figure 3 for experiments of size n = 1, ... , 34. The effects of using this step size on the treatment mean and on expected toxicities were described in Sections 5.2-5.4 and are shown in Tables 3 and 4 In this section, we have demonstrated how exact distribution theory is very useful in planning studies. In particular, being able to calculate the expected proportion of toxic events for experiments of any sample size and any underlying response function is an exciting development in the design of phase I clinical trials.
Discussion
We reiterate the advantages of random walk rules. They satisfy an ethical imperative of minimizing unnecessary assignment of patients to toxic dose levels while allowing for targeting of a specific quantile. Trials tend to concentrate in a region about the target quantile, even when there is a large number of dose levels. Random walk rules do not rely on any distributional assumption for the underlying dose-response curve. They generate designs that are comparable to those of other methods, such as the continual reassessment method, yet they are simpler to implement (for example, the continual reassessment method requires numerical integration). Furthermore, the entire distribution theory for the random walk rules (both finite and asymptotic) has been worked out. No other sequential designs for quantal response of which we are aware have a completely workable distribution theory. It is important to note that many ad hoc up-and-down procedures have been used (e.g., Storer, 1989; Flournoy, 1993 ; the standard method of Korn et al., 1994) without theoretical analysis of their consequences.
It is commonly accepted that phase I clinical trials will focus on toxicity rather than efficacy. However, beyond this common feature, the term is applied in a multitude of experimental settings. Distinguishing features include the experimental objectives and the amount of historical data available on toxicity. Phase I clinical trials include: (1) experiments where the goal is to screen a potentially active agent out of a very large number of potential agents, with a drug passing the screen subjected to further study; (2) experiments where the goal is to investigate new combinations of research drugs that have a long history of use individually or in other combinations; and (3) experiments where drugs with a long history of use for some diseases are tested in patients with other diseases or other stages of the same disease.
In the first situation, the sheer volume of drugs to be screened calls for methods that are quick and often crude, with protection being built into the stages that a new drug must pass through to come to market. On the contrary, when a large amount of historical data on toxicity exists, phase I trial objectives may be much more specific and the objective may be to obtain a regimen that achieves a relatively small improvement (say 20%) over a control. The new regimen may even contain the same drugs as the control, but given according to an alternate schedule. In such cases, it is important that the new regimen be no more toxic than the control. Thus, toxicity in such trials must be determined more precisely than in drug screening studies. Korn et al. (1994) describe a method as standard for phase I clinical trials. This ad hoc method was developed for screening drugs, and it permits highly toxic agents to be identified quickly and allows other drugs to pass to a further stage of testing. It is invariant with respect to levels of toxicity that may be deemed tolerable. Simulation evidence suggests it targets approximately the 20th or 25th percentile.
We have assumed throughout this paper that the lattice and mesh of design points is prespecified. However, our review of Flournoy (1993) clearly demonstrates the undesirable consequences of having a prior response function far from the empirical response function. Hence, the set of dose levels selected as part of the design should be reviewed and revised as needed as the study progresses.
While, for maximum likelihood purposes, we have assumed a logistic model, it should be clear that any location-scale family could be selected for parametric analysis and the performance of the random walk rules themselves are independent of that choice. This is especially important in Bayesian procedures, where the allocation rule depends on the underlying distributional assumption of a parametric prior distribution. The effects of model misspecification in these parametric procedures merits further investigation.
Random walk rules (and most other designs for dose-response studies) are applicable when patient response is obtainable fairly quickly. Fortunately, in many studies, information on patient response is obtainable quickly. When it is not, the one patient per cohort model may be impractical. Random walk rules can be extended to apply to groups of patients in each cohort, provided a rigid definition of toxicity is maintained. Grouped random walk rules were first proposed by Anderson et al. (1946) for estimating the median. Further theoretical work was done by Tsutakawa (1967) , and simulations targeting extreme percentiles can be found in Hsi (1969) and Wetherill and Glazebrook (1986) . Exact properties of grouped random walk designs are forthcoming (H. Wu, unpublished data).
We have also discussed only fixed-sample designs. The full benefit of adaptive designs, such as this random walk rule, is more likely to be attained by incorporating stopping rules. Combining random walk rules with the concepts of sequential analysis opens an array of potential theoretical problems that should be well worth the effort.
